Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Indolent Lymphoproliferative Disorders”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT01429025
What this trial is testing

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma

Who this might be right for
Refractory/Relapsed Indolent Non-Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology 26
Testing effectiveness (Phase 2)Study completedNCT00572013
What this trial is testing

Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma

Who this might be right for
Lymphoma
University of Nebraska 32
Early research (Phase 1)Study completedNCT00082784
What this trial is testing

Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

Who this might be right for
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueNodal Marginal Zone LymphomaRecurrent Adult Diffuse Large Cell Lymphoma+10 more
National Cancer Institute (NCI) 93
Early research (Phase 1)Active Not RecruitingNCT05020678
What this trial is testing

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

Who this might be right for
Lymphoma, Non-HodgkinB-cell Acute Lymphoblastic LeukemiaLarge B-cell Lymphoma+7 more
Nkarta, Inc. 150
Large-scale testing (Phase 3)Study completedNCT03078855
What this trial is testing

Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma

Who this might be right for
Follicular LymphomaSmall Lymphocytic LymphomaMarginal Zone Lymphoma+1 more
Jonathan Friedberg 211
Testing effectiveness (Phase 2)Study completedNCT00069758
What this trial is testing

Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Cephalon 72
Testing effectiveness (Phase 2)Study completedNCT00185692
What this trial is testing

Allogeneic Transplantation From Related Haploidentical Donors

Who this might be right for
Blood CancerLeukemiaGraft Versus Host Disease+5 more
Stanford University 16
Testing effectiveness (Phase 2)UnknownNCT00397800
What this trial is testing

Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Technical University of Munich 12
Large-scale testing (Phase 3)WithdrawnNCT00577161
What this trial is testing

Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL

Who this might be right for
Non-Hodgkin's Lymphoma
CTI BioPharma
Large-scale testing (Phase 3)Looking for participantsNCT06149286
What this trial is testing

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

Who this might be right for
Relapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
Regeneron Pharmaceuticals 580
Early research (Phase 1)Study completedNCT02961881
What this trial is testing

A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Amgen 35
Early research (Phase 1)Ended earlyNCT02483000
What this trial is testing

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

Who this might be right for
Burkitt LymphomaCD20-Positive Neoplastic Cells PresentDiffuse Large B-Cell Lymphoma+4 more
Fred Hutchinson Cancer Center 3
Testing effectiveness (Phase 2)Ended earlyNCT00899353
What this trial is testing

Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)

Who this might be right for
Monoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple MyelomaChronic Lymphocytic Leukemia
Marshall University 16
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06557330
What this trial is testing

MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma

Who this might be right for
LymphomaIndolent Non-hodgkin Lymphoma
Fox Chase Cancer Center 24
Large-scale testing (Phase 3)UnknownNCT01570049
What this trial is testing

Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin Lymphoma by Clinical Course
Shandong Lanjin Pharmaceuticals Co.,Ltd 100
Testing effectiveness (Phase 2)Study completedNCT01995669
What this trial is testing

Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma

Who this might be right for
Grade 3a Follicular LymphomaRecurrent Follicular LymphomaRecurrent Grade 1 Follicular Lymphoma+7 more
M.D. Anderson Cancer Center 66
Testing effectiveness (Phase 2)Ended earlyNCT00005950
What this trial is testing

506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma

Who this might be right for
Angioimmunoblastic T-cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell Lymphoma+7 more
National Cancer Institute (NCI) 111
Large-scale testing (Phase 3)Ended earlyNCT01200589
What this trial is testing

Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy

Who this might be right for
Non-Hodgkin's Lymphoma
Novartis Pharmaceuticals 438
Large-scale testing (Phase 3)Study completedNCT01974440
What this trial is testing

PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma
Janssen Research & Development, LLC 403
Large-scale testing (Phase 3)Ended earlyNCT02626455
What this trial is testing

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

Who this might be right for
Lymphoma, Non-Hodgkin
Bayer 551
Next Page